Daniel Schwartzlose
Private-Equity-Analyst bei NC Advisory A/S
Profil
Daniel Schwartzlose is currently working as an Operations Director at NC Advisory A since 2022.
Prior to this, he worked at Xellia Pharmaceuticals AS as President & Xellia International from 2019 to 2022.
Mr. Schwartzlose has an MBA from the University of Technology Sydney and a graduate degree from the University of Copenhagen.
Aktive Positionen von Daniel Schwartzlose
| Unternehmen | Position | Beginn |
|---|---|---|
| NC Advisory A/S | Private-Equity-Analyst | 01.01.2022 |
Ehemalige bekannte Positionen von Daniel Schwartzlose
| Unternehmen | Position | Ende |
|---|---|---|
Xellia Pharmaceuticals AS
 Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Private Equity Investor | 01.01.2022 |
Ausbildung von Daniel Schwartzlose
| University of Technology Sydney | Masters Business Admin |
| University of Copenhagen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Xellia Pharmaceuticals AS
Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Health Technology |
| NC Advisory A/S | Finance |
